The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498.
 
John H. Sampson
Consulting or Advisory Role - Celldex
Patents, Royalties, Other Intellectual Property - Annias, Intellectual Property
 
Antonio Marcilio Padula Omuro
Consulting or Advisory Role - Bristol-Myers Squibb; Juno Therapeutics; Stemline Therapeutics
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Juno Therapeutics
 
Matthias Preusser
Honoraria - GlaxoSmithKline; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Roche
Research Funding - Boehringer Ingelheim (Inst); GlaxoSmithKline (Inst); Roche (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline; Roche
 
Michael Lim
Honoraria - Accuray; Bristol-Myers Squibb; Merck; Stryker
Consulting or Advisory Role - Accuray; Bristol-Myers Squibb; Merck; Stryker
Research Funding - Accuray (Inst); Agenus (Inst); Arbor Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); CellDex (Inst); ImmunoCellular Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Methods Patent for Combining Immunotherapy with Radiation (Inst)
Travel, Accommodations, Expenses - Accuray; Bristol-Myers Squibb; Merck; Stryker
 
Nicholas A. Butowski
Honoraria - Genentech
Consulting or Advisory Role - Genentech/Roche
Speakers' Bureau - Genentech/Roche
Research Funding - Abbvie; Bristol-Myers Squibb; Lilly; Merrimack; NewGen Therapeutics; Novartis; Proximagen; Stemline Therapeutics
 
Timothy Francis Cloughesy
Consulting or Advisory Role - Abbvie; Agios; Amgen; Celgene; Celldex; cortice; CytRx Corporation; Lpath; Nektar; NewGen Therapeutics; Novartis; Novocure; Oxigene; proximagen; Roche/Genentech; Stemcycle; Tocagen; Upsher-Smith; VBL Therapeutics; wellcome trust
 
Lewis C. Strauss
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Robert Raymond Latek
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Prashni Paliwal
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Michael Weller
Honoraria - Celldex; ImmunoCellular Therapeutics; Isarna Therapeutics; Magforce; Merck; MSD; Northwest Biotherapeutics; Novocure; Pfizer; Roche; Teva
Research Funding - Acceleron Pharma; Actelion; Bayer; Isarna Therapeutics; Merck; MSD; Novocure; Pfizer; Roche
 
David A. Reardon
Honoraria - Abbvie; Cavion; Genentech/Roche; Merck; Midatech Pharma; Momenta Pharmaceuticals; Novartis; Novocure; Regeneron; Stemline Therapeutics
Consulting or Advisory Role - Cavion; Genentech/Roche; Merck; Momenta Pharmaceuticals; Novartis; Novocure; Regeneron; Stemline Therapeutics
Speakers' Bureau - Genentech/Roche; Merck
Research Funding - Celldex (Inst); Incyte (Inst)